These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 19722894)
21. Vector optimization and needle-free intradermal application of a broadly protective polyvalent influenza A DNA vaccine for pigs and humans. Borggren M; Nielsen J; Bragstad K; Karlsson I; Krog JS; Williams JA; Fomsgaard A Hum Vaccin Immunother; 2015; 11(8):1983-90. PubMed ID: 25746201 [TBL] [Abstract][Full Text] [Related]
23. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge. Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689 [TBL] [Abstract][Full Text] [Related]
24. Immunogenicity of Influenza Vaccines: Evidence for Differential Effect of Secondary Vaccination on Humoral and Cellular Immunity. Rosendahl Huber SK; Hendriks M; Jacobi RHJ; van de Kassteele J; Mandersloot-Oskam JC; van Boxtel RAJ; Wensing AMJ; Rots NY; Luytjes W; van Beek J Front Immunol; 2018; 9():3103. PubMed ID: 30761157 [TBL] [Abstract][Full Text] [Related]
25. Epidermal delivery of protein and DNA vaccines. Dean HJ Expert Opin Drug Deliv; 2005 Mar; 2(2):227-36. PubMed ID: 16296750 [TBL] [Abstract][Full Text] [Related]
28. Influenza nucleoprotein DNA vaccination by a skin targeted, dry coated, densely packed microprojection array (Nanopatch) induces potent antibody and CD8(+) T cell responses. Fernando GJ; Zhang J; Ng HI; Haigh OL; Yukiko SR; Kendall MA J Control Release; 2016 Sep; 237():35-41. PubMed ID: 27381247 [TBL] [Abstract][Full Text] [Related]
29. In vivo electroporation enhances immunogenicity and protection against influenza A virus challenge of an M2e-HSP70c DNA vaccine. Jazi MH; Dabaghian M; Tebianian M; Gharagozlou MJ; Ebrahimi SM Virus Res; 2012 Aug; 167(2):219-25. PubMed ID: 22609252 [TBL] [Abstract][Full Text] [Related]
30. Bystander help within a polyepitope DNA vaccine improves immune responses to influenza antigens. Baird M; Wilson R; Young L; Williman J; Young S; Wilson M; Slobbe L; Lockhart E; Buchan G Scand J Immunol; 2004 Oct; 60(4):363-71. PubMed ID: 15379861 [TBL] [Abstract][Full Text] [Related]
31. Selecting and Using the Appropriate Influenza Vaccine for Each Individual. Sekiya T; Ohno M; Nomura N; Handabile C; Shingai M; Jackson DC; Brown LE; Kida H Viruses; 2021 May; 13(6):. PubMed ID: 34073843 [TBL] [Abstract][Full Text] [Related]
32. A polyvalent influenza A DNA vaccine induces heterologous immunity and protects pigs against pandemic A(H1N1)pdm09 virus infection. Bragstad K; Vinner L; Hansen MS; Nielsen J; Fomsgaard A Vaccine; 2013 Apr; 31(18):2281-8. PubMed ID: 23499598 [TBL] [Abstract][Full Text] [Related]
33. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses. Goff PH; Hayashi T; MartÃnez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203 [TBL] [Abstract][Full Text] [Related]
34. Current status and progress of prepandemic and pandemic influenza vaccine development. Leroux-Roels I; Leroux-Roels G Expert Rev Vaccines; 2009 Apr; 8(4):401-23. PubMed ID: 19348557 [TBL] [Abstract][Full Text] [Related]
35. Subunit vaccines based on recombinant yeast protect against influenza A virus in a one-shot vaccination scheme. Gebauer M; Hürlimann HC; Behrens M; Wolff T; Behrens SE Vaccine; 2019 Sep; 37(37):5578-5587. PubMed ID: 31399274 [TBL] [Abstract][Full Text] [Related]
36. Efficacy of seasonal pandemic influenza hemagglutinin DNA vaccines delivered by electroporation against a seasonal H1N1 virus challenge in mice. Tan L; Lu H; Zhang D; Wang K; Tian M; Liu C; Liu Y; Hu B; Jin N Sci China Life Sci; 2011 Apr; 54(4):293-9. PubMed ID: 21416231 [TBL] [Abstract][Full Text] [Related]
37. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Smith LR; Wloch MK; Ye M; Reyes LR; Boutsaboualoy S; Dunne CE; Chaplin JA; Rusalov D; Rolland AP; Fisher CL; Al-Ibrahim MS; Kabongo ML; Steigbigel R; Belshe RB; Kitt ER; Chu AH; Moss RB Vaccine; 2010 Mar; 28(13):2565-72. PubMed ID: 20117262 [TBL] [Abstract][Full Text] [Related]